TRDA: Entrada Company Value to Net Income

Entrada Therapeutics (TRDA) is protected by its exclusive EEV system for brain therapy, which creates insurmountable barriers for competitors under strict FDA oversight. This chart reflects an asset value of -1.20. Entrada Therapeutics (TRDA) attracts leading biochemists through stock option programs, preserving its valuable R&D potential. The business relies on developing gene therapies for rare muscle pathologies with high profitability.

Entrada - TRDA P/E Multiple (period 08/14/2022 - 11/14/2026)

Analytical breakdowns for Entrada Therapeutics

- price and consensus price forecast:

Stock Price entradatx.com|TRDA - Consensus Target

- market capitalization information:

Market Value Entrada Therapeutics, Inc.|TRDA - Total Company Value

- balance sheet net asset value indicators:

Equity per Share Entrada Therapeutics|TRDA - Book Capitalization|Market-to-Book Ratio entradatx.com|TRDA - Cumulative Company Assets

- company liabilities and liquidity data:

- financial results and valuation multiples details:

TRDA - Net Profit|Projected Net Profit Entrada Therapeutics|TRDA - Price to Earnings Ratio|Projected Price to Earnings Ratio Entrada Therapeutics Inc.|TRDA - PEG Multiple|Company Value to EBITDA Entrada Therapeutics, Inc.|TRDA - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Entrada Therapeutics|TRDA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months entradatx.com|TRDA - Earnings per share growth in current year|Expected earnings per share trend next year Entrada Therapeutics

- company sales and revenue statistics:

TRDA - Revenue and Sales Volume|Projected Sales Volume entradatx.com|TRDA - P/S Multiple|Market Cap to Projected Revenue Entrada Therapeutics, Inc.

Comprehensive company analysis:TRDA (entradatx.com)

Core merchandise of Entrada Therapeutics, Inc

Investors use this ratio to distinguish sustainable enterprises from loss-making assets. The metric correlates the market value of the business with its net profit, identifying either an unjustified premium or the risk of purchasing a fading model. By analyzing the quarterly P/E of Entrada Therapeutics (TRDA), one can assess the fairness of the price considering the unique EEV platform. The strong pricing power of Entrada Therapeutics (TRDA) in Duchenne muscular dystrophy therapy should fundamentally justify current market expectations.

Analysis of competing companies